<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833155</url>
  </required_header>
  <id_info>
    <org_study_id>EOC103-001</org_study_id>
    <nct_id>NCT02833155</nct_id>
  </id_info>
  <brief_title>Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I and Pharmacokinetic Study to Evaluate Histone Deacetylase Inhibitor, Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taizhou EOC Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taizhou EOC Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerance of entinostat administered&#xD;
      orally as a single agent in a weekly dosing schedule. Additionally, this study will&#xD;
      characterize the pharmacokinetics parameters in Chinese postmenopausal women with advanced&#xD;
      breast cancer. And to define the profile of adverse events, including laboratory parameters&#xD;
      in these subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2016</start_date>
  <completion_date type="Actual">July 18, 2018</completion_date>
  <primary_completion_date type="Actual">July 18, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, 12-lead ECG, blood pressure/pulse, temperature, laboratory parameters and physical examination.</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax,maximum plasma concentration</measure>
    <time_frame>Pre-dose, Days 1,2,3,4,5,7,15 and 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,time at which maximum plasma concentration was observed</measure>
    <time_frame>Pre-dose, Days 1,2,3,4,5,7,15 and 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-168h area under the plasma concentration-time curve from time zero to 168h</measure>
    <time_frame>Pre-dose, Days 1,2,3,4,5 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-inf,area under the plasma concentration-time curve from time zero to infinity</measure>
    <time_frame>Pre-dose, Days 1,2,3,4,5,7,15 and 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2, elimination half-life</measure>
    <time_frame>Pre-dose, Days 1,2,3,4,5,7,15 and 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lambda z , apparent terminal phase elimination constant (λz)</measure>
    <time_frame>Pre-dose, Days 1,2,3,4,5,7,15 and 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT，mean residence time</measure>
    <time_frame>Pre-dose, Days 1,2,3,4,5,7,15 and 22</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Entinostat and Exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive entinostat PO on days 1, 8, 15, and 22. Entinostat in combination with exemestane will be repeatedly administered every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Exemestane wil be orally administered once daily for up to six months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Entinostat and Exemestane</arm_group_label>
    <other_name>MS-275</other_name>
    <other_name>SDNX-275</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Entinostat and Exemestane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For inclusion in the study patients should fulfil the following criteria:&#xD;
&#xD;
          -  Provision of informed consent prior to any study specific procedures.&#xD;
&#xD;
          -  Postmenopausal women aged ≤ 65years.&#xD;
&#xD;
          -  Estrogen receptor (ER) and / or progesterone receptor (PR) positive breast cancer&#xD;
             confirmed by pathology.&#xD;
&#xD;
          -  Once received a non-steroidal aromatase inhibitor (letrozole / anastrozole) treatment,&#xD;
             the disease recurrence or progression of breast cancer currently.&#xD;
&#xD;
          -  Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.&#xD;
             And recently (past 2 months), weight loss is no more than 10% of average weight.&#xD;
&#xD;
          -  Patients must have a life expectancy &gt;3 months.&#xD;
&#xD;
          -  Patients must have adequate organ and bone marrow function as defined by the following&#xD;
             laboratory results.&#xD;
&#xD;
               1. .absolute neutrophil count ( ANC )≥ 1,500 /mm3&#xD;
&#xD;
               2. . Platelets≥100,000 /mm3&#xD;
&#xD;
               3. . White blood cell count(WBC） ≥ 3,000 /mm3&#xD;
&#xD;
               4. . Hemoglobin ≥ 9 g/dL.&#xD;
&#xD;
               5. . Creatinine ≤ 1.5 times the upper limit of normal (ULN) for the institution or&#xD;
                  Creatinine clearance ≥ 60 ml/min/1.73m2&#xD;
&#xD;
               6. . Total bilirubin ≤ 1.5 times the upper limit of normal for the institution(ULN)&#xD;
&#xD;
               7. .Aspartate transaminases (AST/SGOT) or alanine transaminase (ALT/SGPT) ≤ 2.5&#xD;
                  times the upper limit.&#xD;
&#xD;
          -  Patients must be able to take drugs and don't spit out, no malabsorption problem.&#xD;
&#xD;
          -  Able to comply with study procedures and follow-up examinations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients have known central nervous system metastasis except patients who have&#xD;
             terminated steroid treatment for brain metastasis or spinal cord compression with&#xD;
             remain disease stable for at least 1 month.&#xD;
&#xD;
          -  Previous treatment with entinostat or any other histone deacetylase inhibitor&#xD;
             (Valproic acid, Chidamide etc).&#xD;
&#xD;
          -  Known allergy to any ingredients of entinostat and other drugs in the same class.&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding (premenopausal). For women of childbearing&#xD;
             potential, agreement to use a medically approved contraception measures (such as the&#xD;
             intrauterine device (IUD), birth control pills or condoms) and to continue its use for&#xD;
             the duration of study treatment and for 3 months after the last dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Had received chemotherapy/radiotherapy or other anticancer therapy during the study or&#xD;
             within 4 weeks of start of study treatment. Patients must completely recovered from&#xD;
             all adverse events due to previous agents administered before 4 weeks (except&#xD;
             alopecia).&#xD;
&#xD;
          -  Major surgery within 28 days of start of study treatment.&#xD;
&#xD;
          -  Patients have serious or uncontrolled systemic disease (such as severe liver&#xD;
             dysfunction, severe renal dysfunction, poorly controlled diabetes, poorly controlled&#xD;
             acute infections). Unstable or decompensated respiratory or cardiovascular disease, or&#xD;
             peripheral vascular disease (including diabetic vascular disease), or organ&#xD;
             transplantation.&#xD;
&#xD;
          -  Received potent CYP1A2 or CYP3A4 inducer and/or inhibitor (including but not limited&#xD;
             following drug: ketoconazole, rifampicin, atazanavir, Clarithromycin, indinavir,&#xD;
             itraconazole, nelfinavir, saquinavir, telithromycin, voriconazole, grapefruit or&#xD;
             grapefruit juice, rifabutin, phenytoin, Carbamazepine and phenobarbital).&#xD;
&#xD;
          -  Patients with another active cancer (excluding basal cell carcinoma or cervical&#xD;
             intraepithelial neoplasia [cervical intraepithelial neoplasia （CIN）/cervical carcinoma&#xD;
             in situ] or melanoma in-situ). Prior history of other cancer is allowed, as long as&#xD;
             there is no active disease within the prior 5 years.&#xD;
&#xD;
          -  Active bleeding or new thrombotic diseases using of anticoagulant drugs, patients with&#xD;
             bleeding tendency.&#xD;
&#xD;
          -  Meet with any of the following criteria about cardiac parameters:&#xD;
&#xD;
          -  the corrected QT interval (QTc) &gt;470 msec under resting conditions.&#xD;
&#xD;
          -  myocardial infarction or arterial thrombosis events within 6 months, or experiencing&#xD;
             severe or unstable angina, or New York Heart Association (NYHA) Class III or IV&#xD;
             disease.&#xD;
&#xD;
          -  Resting ECG imply any clinically significant abnormal on rhythm, conduction and&#xD;
             morphology, for example, left bundle branch block, third degree heart block, second&#xD;
             degree heart block, PR interval &gt; 250 msec.&#xD;
&#xD;
          -  Any factors (such as, heart failure, hypokalemia, inherited long QT syndrome, acquired&#xD;
             long QT syndrome or family history of unexplained sudden death in immediate family&#xD;
             members under 40 years old) or known combined drug (such as, sotalol, cisapride,&#xD;
             clozapine, amiodarone and erythromycin, etc.) to increase risk of prolongation of QTc&#xD;
             interval or arrhythmic event.&#xD;
&#xD;
          -  History of or known human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Known drug or long-term alcoholics.&#xD;
&#xD;
          -  Patient is currently enrolled in (or completed within 30 days before study drug&#xD;
             administration) another investigational drug study.&#xD;
&#xD;
          -  Involvement in the planning and conduct of the study.&#xD;
&#xD;
          -  Possible of lower inclusion criteria according to the researchers (such as weak, etc),&#xD;
             or the other is not suitable for this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>entinostat</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Entinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

